These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21718326)

  • 21. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Amyloid positron-emission-tomography with [
    Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
    Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New PET markers for the diagnosis of dementia.
    Payoux P; Salabert AS
    Curr Opin Neurol; 2017 Dec; 30(6):608-616. PubMed ID: 28906268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Technical Considerations on Scanning and Image Analysis for Amyloid PET in Dementia].
    Akamatsu G; Ohnishi A; Aita K; Ikari Y; Yamamoto Y; Senda M
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2017; 73(4):298-308. PubMed ID: 28428473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management impact of FDG-PET in dementia: results from a tertiary center memory clinic.
    Elias A; Woodward M; Rowe CC
    J Alzheimers Dis; 2014; 42(3):885-92. PubMed ID: 24961944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular imaging of cerebral blood flow and metabolism with SPET and PET in principal dementias].
    Gerasimou G; Bostantjopoulou S; Gotzamani-Psarrakou A
    Hell J Nucl Med; 2009; 12(1):79-83. PubMed ID: 19330195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Relevance of [
    Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study.
    Panegyres PK; Rogers JM; McCarthy M; Campbell A; Wu JS
    BMC Neurol; 2009 Aug; 9():41. PubMed ID: 19674446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies.
    Dukart J; Mueller K; Horstmann A; Vogt B; Frisch S; Barthel H; Becker G; Möller HE; Villringer A; Sabri O; Schroeter ML
    Neuroimage; 2010 Jan; 49(2):1490-5. PubMed ID: 19770055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis.
    Hellwig S; Domschke K; Meyer PT
    Curr Opin Neurol; 2019 Aug; 32(4):548-556. PubMed ID: 31107281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography.
    Brooks DJ
    Mov Disord; 2009; 24 Suppl 2():S742-7. PubMed ID: 19877240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating 2-[
    Gjerum L; Frederiksen KS; Henriksen OM; Law I; Bruun M; Simonsen AH; Mecocci P; Baroni M; Dottorini ME; Koikkalainen J; Lötjönen J; Hasselbalch SG
    Neuroimage Clin; 2020; 27():102267. PubMed ID: 32417727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interpretation of Biomarker Data in Diagnosis of Primary Dementias.
    Salardini A
    Semin Neurol; 2019 Apr; 39(2):200-212. PubMed ID: 30925613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autopsy as gold standard in FDG-PET studies in dementia.
    Durand-Martel P; Tremblay D; Brodeur C; Paquet N
    Can J Neurol Sci; 2010 May; 37(3):336-42. PubMed ID: 20481267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroimaging in Dementias.
    Mahalingam S; Chen MK
    Semin Neurol; 2019 Apr; 39(2):188-199. PubMed ID: 30925612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current and future prospects of nuclear medicine in dementia].
    Ito K; Inui Y; Kizawa T; Kimura Y; Kato T
    Rinsho Shinkeigaku; 2017 Sep; 57(9):479-484. PubMed ID: 28804110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.
    Wren MC; Lashley T; Årstad E; Sander K
    Acta Neuropathol Commun; 2018 May; 6(1):34. PubMed ID: 29716656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET studies in dementia.
    Herholz K
    Ann Nucl Med; 2003 Apr; 17(2):79-89. PubMed ID: 12790355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?].
    Grimmer T; Drzezga A; Kurz A
    Nervenarzt; 2010 May; 81(5):602-6. PubMed ID: 20221742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.